Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions Islam Y. ElgendyLina Ya’QoubCarl J. Pepine Leading Article 29 January 2022 Pages: 241 - 250
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder Elizabeth M. BurnetteSteven J. NietoLara A. Ray Review Article Open access 08 February 2022 Pages: 251 - 274
Pharmacologic Management of Persistent Pain in Cancer Survivors Paul GlareKarin AubreySarah Overton Review Article Open access 17 February 2022 Pages: 275 - 291
Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature Luis F. RendonIshaan A. TewarieRania A. Mekary Systematic Review 05 February 2022 Pages: 293 - 310
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases Tian LiRui ProvidenciaHeng Ma Original Research Article 15 January 2022 Pages: 311 - 322
Ocrelizumab: A Review in Multiple Sclerosis Yvette N. Lamb Adis Drug Evaluation 22 February 2022 Pages: 323 - 334
Efgartigimod: First Approval Young-A Heo AdisInsight Report Open access 18 February 2022 Pages: 341 - 348
Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence” Mario Gennaro MazzaBenedetta VaiRaffaella Zanardi Letter to the Editor 12 February 2022 Pages: 349 - 351
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence” Eric J. LenzeAngela M. ReiersenShelley N. Facente Letter to the Editor 12 February 2022 Pages: 353 - 354
Correction to: Ocular Toxicity of Targeted Anticancer Agents Blake H. FortesPrashant D. TailorLauren A. Dalvin Correction 15 February 2022 Pages: 355 - 355
